Starling Oncology, Inc. (STLN)
| Market Cap | 683.86M +66.6% |
| Revenue (ttm) | 587.24M +38.4% |
| Net Income | -30.56M |
| EPS | -0.30 |
| Shares Out | 101.92M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,055,649 |
| Open | 6.92 |
| Previous Close | 6.91 |
| Day's Range | 6.66 - 6.96 |
| 52-Week Range | 2.32 - 7.13 |
| Beta | 0.42 |
| Analysts | Strong Buy |
| Price Target | 9.40 (+40.09%) |
| Est. Earnings | Nov 12, 2026 |
About STLN
Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliative car... [Read more]
Financial Performance
In 2025, Starling Oncology's revenue was $502.73 million, an increase of 27.79% compared to the previous year's $393.41 million. Losses were -$50.31 million, -5.09% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for STLN stock is "Strong Buy." The 12-month stock price target is $9.4, which is an increase of 40.09% from the latest price.
News
Starling Oncology price target raised to $9 from $7 at Needham
Needham raised the firm’s price target on Starling Oncology (STLN) to $9 from $7 and keeps a Buy rating on the shares after hosting a non-deal roadshow with its CEO…
Starling Oncology management to meet with B. Riley
Meeting to be held in South Florida on October 8-9 hosted by B. Riley.
Starling Oncology management to meet with Needham
Meeting to be held in New York on October 13 hosted by Needham.
Starling Oncology Leadership Highlights Recent and Upcoming Industry Conference Participation
Physician leaders share clinical insights on value-based therapy delivery, clinical trial access and integrated behavioral health in community oncology at major industry forums Physician leaders share...
Starling Oncology Transcript: Wells Fargo 21st Annual Healthcare Conference
Achieved first fully profitable year, doubled down on capital-light growth, and expanded delegated contracts across multiple states. Pharmacy now drives over 60% of revenue with rising margins, and robust pipeline supports a 2027 goal to double capitated revenue.
Starling Oncology Slides: Investor presentation
Starling Oncology has posted slides in relation to its latest quarterly earnings report, which was published on September 8, 2026.
Starling Oncology to Participate in Wells Fargo Healthcare Conference
CERRITOS, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Starling Oncology™, Inc. (NASDAQ: STLN), (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, t...
Starling Oncology Launches Starling Nexus™, a Technology Platform Built to Optimize Oncology Provider Engagement and Accelerate High-Quality Care at Scale
CERRITOS, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Starling Oncology™ Inc. (NASDAQ: STLN), (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, to...
Starling Oncology price target raised to $11 from $8 at B. Riley
B. Riley raised the firm’s price target on Starling Oncology (STLN) to $11 from $8 and keeps a Buy rating on the shares. The company guided capitated revenue to double…
Starling Oncology Earnings Call Transcript: Q2 2026
Q2 2026 saw record revenue, positive adjusted EBITDA, and a successful refinancing that improved liquidity. New capitation contracts in Nevada, Oregon, and California drove growth, while guidance for 2026 was raised on strong specialty pharmacy performance.
Starling Oncology Earnings release: Q2 2026
Starling Oncology released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Starling Oncology Quarterly report: Q2 2026
Starling Oncology has published its Q2 2026 quarterly earnings report on August 6, 2026.
Starling Oncology Reports Second Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance
CERRITOS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, tod...
The Oncology Institute Rebrands as Starling Oncology
CERRITOS, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI" or “the Company”), one of the largest value-based oncology groups in the United States, announced today that it ...
The Oncology Institute Announces Second Quarter 2026 Earnings Release Date and Conference Call
CERRITOS, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI) a pioneer in value-based community oncology care, today announced that the company will release i...
The Oncology Institute Completes Strategic Refinancing with OrbiMed, Repaying the Outstanding $86 Million Deerfield Convertible Note, Strengthening its Balance Sheet, and Improving Liquidity
CERRITOS, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, announced today that it has...
Starling Oncology Slides: Investor presentation
Starling Oncology has posted slides in relation to its latest quarterly earnings report, which was published on June 16, 2026.
Topicus.com Inc. Announces a Revised Proposal to Acquire ReadyTech
TORONTO, May 31, 2026 (GLOBE NEWSWIRE) -- Topicus.com Inc. (TSXV: TOI), acting through its subsidiary TSS Europe B.V. (“TSS”), today submitted a revised non-binding indicative proposal to acquire Read...
The Oncology Institute Chief Medical Officer to Speak on Value-Based Specialty Care at APG Spring Conference
CERRITOS, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Yale D.
Starling Oncology Slides: Investor presentation
Starling Oncology has posted slides in relation to its latest quarterly earnings report, which was published on May 20, 2026.
The Oncology Institute to Participate in B. Riley Securities Institutional Investor Conference
CERRITOS, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Dr. Daniel Virn...
Starling Oncology Earnings Call Transcript: Q1 2026
Q1 2026 saw 41% revenue growth, record specialty pharmacy performance, and profitability in Florida. Guidance for revenue, adjusted EBITDA, and free cash flow was reaffirmed or raised, with ongoing expansion in value-based contracts and AI-driven efficiencies.
Starling Oncology Quarterly report: Q1 2026
Starling Oncology has published its Q1 2026 quarterly earnings report on May 7, 2026.
Starling Oncology Earnings release: Q1 2026
Starling Oncology released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
The Oncology Institute Reports First Quarter 2026 Financial Results
CERRITOS, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, t...